{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:57Z","timestamp":1707525117501},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,20]]},"DOI":"10.7759\/cureus.42199","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T15:36:15Z","timestamp":1689867375000},"source":"Crossref","is-referenced-by-count":0,"title":["A Novel Presentation of Refractory Immune Thrombocytopenia in Anti-synthetase Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Robert D","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao H","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siob\u00e1n","family":"Keel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi J","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, Wang G. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017, 44:1051-7. 10.3899\/jrheum.161480","journal-title":"J Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318260977c","article-title":"Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature","volume":"91","author":"Labirua-Iturburu A","year":"2012","unstructured":"Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al.. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012, 91:206-11. 10.1097\/MD.0b013e318260977c","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.28.1.20","article-title":"Lupus thrombocytopenia: pathogenesis and therapeutic implications","volume":"28","author":"Galanopoulos N","year":"2017","unstructured":"Galanopoulos N, Christoforidou A, Bezirgiannidou Z. Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterr J Rheumatol. 2017, 28:20-6. 10.31138\/mjr.28.1.20","journal-title":"Mediterr J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury CA","year":"2021","unstructured":"Bradbury CA, Pell J, Hill Q, et al.. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021, 385:885-95. 10.1056\/NEJMoa2100596","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S47240","article-title":"Romiplostim as a treatment for immune thrombocytopenia: a review","volume":"6","author":"Chalmers S","year":"2015","unstructured":"Chalmers S, Tarantino MD. Romiplostim as a treatment for immune thrombocytopenia: a review. J Blood Med. 2015, 6:37-44. 10.2147\/JBM.S47240","journal-title":"J Blood Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"Al-Samkari H","year":"2019","unstructured":"Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019, 10:2040620719841735. 10.1177\/2040620719841735","journal-title":"Ther Adv Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12586","article-title":"Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients","volume":"96","author":"Stirnemann J","year":"2016","unstructured":"Stirnemann J, Kaddouri N, Khellaf M, et al.. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016, 96:269-75. 10.1111\/ejh.12586","journal-title":"Eur J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa717","article-title":"A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura","volume":"60","author":"Goreshnik A","year":"2021","unstructured":"Goreshnik A, Serling-Boyd N, Theodore M, Champion S, Stemmer-Rachamimov A, Sykes DB. A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura. Rheumatology (Oxford). 2021, 60:e143-5. 10.1093\/rheumatology\/keaa717","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006529","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous O","year":"2020","unstructured":"Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020, 135:472-490. 10.1182\/blood.2020006529","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001380","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"4","author":"Neunert C","year":"2020","unstructured":"Neunert C, Terrell DR, Arnold DM, et al.. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2020, 4:252. 10.1182\/bloodadvances.2019001380","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle TJ","year":"2018","unstructured":"Doyle TJ, Dhillon N, Madan R, et al.. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol. 2018, 45:841-50. 10.3899\/jrheum.170541","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya JA","year":"2019","unstructured":"Huapaya JA, Silhan L, Pinal-Fernandez I, et al.. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest. 2019, 156:896-906. 10.1016\/j.chest.2019.05.023","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/156775-a-novel-presentation-of-refractory-immune-thrombocytopenia-in-anti-synthetase-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:01Z","timestamp":1707508861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/156775-a-novel-presentation-of-refractory-immune-thrombocytopenia-in-anti-synthetase-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.42199","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}